|
Long-Term Analysis of Patients With Ewing Sarcoma Included in the Euro-EWING99 Study
Jul 31, 2026 Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab Jul 31, 2026 Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide Jul 31, 2026 Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab Jul 31, 2026 Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide Jul 31, 2026 High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation Jul 30, 2026 Dexamethasone-Free Antiemetic Prophylaxis for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: A Multicenter, Phase III, Noninferiority Trial (CIVIC POD) Jul 30, 2026 Limiting Dexamethasone Exposure With Highly Emetogenic Chemotherapy Regimens: Is the Verdict In? Jul 30, 2026 Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial Jul 30, 2026 Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL Jul 29, 2026 Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial Jul 29, 2026 COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer Jul 29, 2026 Rethinking Regulatory Protections for Accelerated Approvals With Supplementary Indications Jul 29, 2026 He Was Always There Jul 28, 2026 Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial Jul 27, 2026 SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer Jul 27, 2026 Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer Jul 27, 2026 Time-Varying Effects of Copy Number Alteration Clustering: Methodologic Concerns in Survival Analysis of Relapsed/Refractory Germ Cell Tumors Jul 27, 2026 Anti-TIGIT in PD-L1–High Advanced Non–Small Cell Lung Cancer: Insights From SKYSCRAPER-01 and the Path Forward Jul 27, 2026 Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801) Jul 27, 2026 |
He Was Always There Journal of Clinical Oncology, Volume 44, Issue 26, Page 2554-2556, September 2026. <br/> 2026-09-10T07:00:00Z Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study Journal of Clinical Oncology, Volume 44, Issue 26, Page 2529-2542, September 2026. <br/> 2026-09-10T07:00:00Z Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer Journal of Clinical Oncology, Volume 44, Issue 26, Page 2507-2516, September 2026. <br/> 2026-09-10T07:00:00Z COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma Journal of Clinical Oncology, Volume 44, Issue 26, Page 2490-2495, September 2026. <br/> 2026-09-10T07:00:00Z Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) Journal of Clinical Oncology, Volume 44, Issue 26, Page 2543-2553, September 2026. <br/> 2026-09-10T07:00:00Z Development and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer Journal of Clinical Oncology, Volume 44, Issue 26, Page 2496-2506, September 2026. <br/> 2026-09-10T07:00:00Z Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study Journal of Clinical Oncology, Volume 44, Issue 26, Page 2517-2528, September 2026. <br/> 2026-09-10T07:00:00Z Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2 Journal of Clinical Oncology, Volume 44, Issue 26, Page e127-e139, September 2026. <br/> 2026-09-10T07:00:00Z Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study Journal of Clinical Oncology, Volume 44, Issue 26, Page 2482-2489, September 2026. <br/> 2026-09-10T07:00:00Z Oncology Drug Development: Challenges of Increasingly Available Therapies Journal of Clinical Oncology, Volume 44, Issue 26, Page 2471-2475, September 2026. <br/> 2026-09-10T07:00:00Z Sustaining High Reliability Amid Artificial Intelligence Adoption in Oncology Journal of Clinical Oncology, Volume 44, Issue 26, Page 2476-2481, September 2026. <br/> 2026-09-10T07:00:00Z Role of Risk-Reducing Bilateral Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers Journal of Clinical Oncology, Volume 44, Issue 26, Page 2560-2561, September 2026. <br/> 2026-09-10T07:00:00Z Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy Journal of Clinical Oncology, Volume 44, Issue 26, Page 2557-2558, September 2026. <br/> 2026-09-10T07:00:00Z Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials Journal of Clinical Oncology, Volume 44, Issue 26, Page 2563-2563, September 2026. <br/> 2026-09-10T07:00:00Z Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions Journal of Clinical Oncology, Volume 44, Issue 26, Page 2563-2564, September 2026. <br/> 2026-09-10T07:00:00Z Reply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy Journal of Clinical Oncology, Volume 44, Issue 26, Page 2558-2560, September 2026. <br/> 2026-09-10T07:00:00Z |
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher. 2026-09-12
Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease The authors report the results of interim analyses of two phase 3 studies of exa-cel, a gene-edited cellular therapy, in children with transfusion-dependent β-thalassemia or sickle cell disease. 2026-09-10
Outbreak of Severe Methemoglobinemia during Maritime Migration Severe acquired methemoglobinemia was identified in 82 migrants disembarking in Sicily, 74 of whom were treated with methylene blue. Dermal absorption of N-methylaniline was identified as the likely cause. 2026-09-10
Treatment Decisions in Multiple Myeloma The authors summarize treatment for multiple myeloma, highlighting four-drug induction therapy, evolving transplantation strategies, tailored maintenance therapy, and in relapse, earlier use of BCMA-directed immunotherapy. 2026-09-10
Advancing Gene Editing for Children with Hemoglobinopathies Sickle cell disease and β-thalassemia are highly prevalent inherited conditions associated with serious complications and a shortened life span. Transfusions in patients with severe β-thalassemia and hydroxyurea therapy in those with sickle cell disease can improve outcomes for many of these patients, yet early diagnosis, consistent access to safe blood... 2026-09-10
The Long Shadow of Bedlam A dying patient in a state psychiatric hospital has no access to a DNR order that would make the process as peaceful as possible — as the notorious Bedlam casts a shadow over mental health care to this day. 2026-09-10
Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy A 3-year-old boy with chemotherapy-resistant metastatic hepatoblastoma had complete regression lasting at least 12 months after two infusions of glypican-3–specific CAR T cells coexpressing interleukin-15 and interleukin-21. 2026-09-10
Reengineering Coagulation with a Bispecific Antibody Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa, who developed a prophylactic therapy for hemophilia A, have received the 2026 Lasker–DeBakey Clinical Medical Research Award. 2026-09-09
Daraxonrasib for Previously Treated RAS-Mutant Non–Small-Cell Lung Cancer In a phase 1–2 study of daraxonrasib, 54% of patients with RAS-mutant non–small-cell lung cancer had grade 3 or higher adverse events, mainly pneumonia, diarrhea, and rash; more than 30% of patients had a response. 2026-09-03
Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia In a randomized phase 2 trial involving adults with AML, azacitidine–venetoclax led to longer event-free survival than induction chemotherapy, with a lower risk of severe infection and hemorrhage. 2026-09-03
Pulmonary Nodules This review summarizes the management of pulmonary nodules, with an emphasis on nodule type, imaging follow-up, cancer risk, and strategies to balance timely diagnosis with avoidance of unnecessary procedures. 2026-09-03
Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML I first treated a patient with leukemia with the so-called “7+3” regimen (a 7-day continuous infusion of cytarabine plus three daily infusions of an anthracycline, usually daunorubicin)1 more than 50 years ago during my residency. To be candid, I had little understanding of what I was doing but... 2026-09-03
Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders Among 16 patients with refractory neurologic autoimmune disorders, lentiviral CD19 CAR T-cell therapy was associated with manageable side effects, complete B-cell depletion, and preliminary clinical improvement across disease groups. 2026-09-03
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations In NSCLC with EGFR exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia. 2026-08-20
Myeloproliferative Neoplasms This review summarizes the pathogenesis and treatment of myeloproliferative neoplasms, highlighting the role of driver mutations, inflammation, and emerging targeted therapies that may achieve durable disease modification. 2026-08-20
Marijuana Rescheduling — A Game Changer for Research? A proposed reclassification of medical marijuana products as Schedule III drugs would address only two of the three key barriers to research on marijuana’s safety and effectiveness for various indications. 2026-08-20
Severe Plasmodium falciparum Malaria An 82-year-old man was brought to the ED after being “found down.” One week earlier, he had returned from a 1-month visit to Chad. A peripheral-blood smear showed ring-form trophozoites within erythrocytes. 2026-08-20
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer Among patients with RET fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels. 2026-08-13
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events. 2026-08-13
Warthin Tumors A 55-year-old man with a smoking history of 10 pack-years presented with 2 years of an enlarging, painless lump below his right ear. A previously unnoticed smaller mass in the left parotid gland was seen on examination. 2026-08-13
|
|
|
| |||
|
[Editorial] Beyond cancer: The Right to be Forgotten
In Germany, politicians are pressing the government to end discrimination against people in remission from cancer. Germany remains among the European outliers in obstructing a fresh start for former patients. A petition campaigning under the slogan, “Healed. And Yet Disadvantaged”, has gathered over 56 000 signatures. Tue, 01 Sep 2026 00:00:00 -0700
[Comment] STAR-TREC and TESAR trials: strengthening the evidence for organ preservation in rectal cancer The adoption of total mesorectal excision (TME) has significantly reduced the risk of locoregional recurrence in patients with rectal cancer. However, this reduction comes at the cost of substantial treatment-related morbidity, including permanent stoma formation and long-term impairment of bowel, urinary, and sexual function that adversely impact quality of life (QOL) and functionality.1 As such, management has evolved toward risk-adapted, patient-centred strategies, including selective organ preservation that is oncologically safe and associated with better QOL. Sun, 23 Aug 2026 22:30:02 +0000
[Comment] Radiotherapy dose intensification for high-risk prostate cancer—what is gained? Can a modest increase in radiotherapy dose make a difference for a patient with high-risk prostate cancer? In The Lancet Oncology, Christophe Hennequin and colleagues present results from the GETUG-AFU 18 trial,1 which enrolled 505 patients across 25 centres in France to answer this important and relevant question. Participants were randomly assigned (1:1) to receive 70 Gy or 80 Gy to the prostate, along with 3 years of androgen deprivation therapy (ADT). The higher radiotherapy dose improved biochemical or clinical progression-free survival (the primary outcome) from 88·1% to 91·4% at 5 years and from 72·2% to 83·6% at 10 years (stratified hazard ratio 0·56, 95% CI 0·40–0·78). Tue, 01 Sep 2026 00:00:00 -0700
[Comment] Beyond visual tumour-infiltrating lymphocytes assessment Stromal tumour-infiltrating lymphocytes (sTILs) have become one of the most clinically informative immune biomarkers in breast cancer,1 associated with improved response to systemic therapy and favourable long-term outcomes.2,3 Reproducibility is not the obstacle to their use. In a secondary analysis of the APHINITY trial in The Lancet Oncology, Luis E Lara González and colleagues4 found a high interobserver reproducibility among five pathologists scoring 262 cases to international guidelines.5 However, scoring requires expert pathologists, quality-assured haematoxylin and eosin slides, and time, which are unevenly distributed across health systems. Tue, 01 Sep 2026 00:00:00 -0700
[Comment] Afghan women's cancer crisis deserves its own response Non-communicable diseases (NCDs) already account for an estimated 43% of all deaths in Afghanistan1 and are projected to exceed 60% by 2030, mainly among women. However, access to cancer care remains critically limited—Afghanistan has only two functioning cancer treatment centres, both in Kabul (Jamhuriat Hospital and the newly opened National Cancer Diagnosis and Treatment Hospital), for more than 40 million people, and neither offers radiotherapy.2 These gaps contribute to delayed diagnosis, poor outcomes, and avoidable mortality, and highlight the urgent need to strengthen cancer prevention, detection, and treatment nationwide. Tue, 01 Sep 2026 00:00:00 -0700
[Comment] Cancer care in Canada Canada's cancer care system has achieved substantial progress through advances in cancer prevention, screening, early detection, and treatment, including targeted therapies and immunotherapy.1 Although both the age-standardised incidence rate and age-standardised mortality rate (ASMR) continue to decline, an estimated 254 100 Canadians will be diagnosed with cancer and an estimated 87 900 will die from the disease in 2026.2 Tue, 01 Sep 2026 00:00:00 -0700
[Correspondence] Closing the gap in southeast Asia's diagnostic molecular oncology testing We welcome The Lancet Oncology Commission highlighting the global cancer workforce crisis, which projects a shortage of 9·47 million diagnostic (pathology and imaging) specialists in Asia by 2050 and identifies pathologists as yielding the highest return on investment in the region (US$35·4 per $1 invested).1 Although the Commission focuses primarily on Africa and Latin America, southeast Asia offers a compelling example of how diagnostic workforce shortages and limited laboratory capacity directly constrain access to precision oncology. Tue, 01 Sep 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 686–98 Brunt AM, Cafferty FH, Kirby AM, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy. Lancet Oncol 2026; 27: 686–98—The appendix of this Article has been corrected as of Aug 24, 2026. Tue, 01 Sep 2026 00:00:00 -0700
[News] UK study to report cancer risk in armed services personnel The UK Government has announced it is to conduct a study into cancer risk in armed services personnel, both past and present. The UK's Ministry of Defence says the study is part of its efforts to improve the long-term health of those who serve and have served in the armed services. The UK-wide epidemiological study (covering all four nations) will examine cancer incidence among those who have served since 1990, including some 1·4 million currently serving and veterans. No personnel will need to take action to be included in the study, as it will use existing records held in by the country's National Health Service (NHS). Thu, 23 Jul 2026 22:30:01 +0000
[News] Sweden plans to restrict PFAS On July 23, 2026, the Government of Sweden announced plans to prohibit perfluoroalkyl and polyfluoroalkyl substances (PFAS), also called forever chemicals, in certain consumer products such as clothing, footwear, cosmetics, and kitchen utensils starting Jan 1, 2028. This plan will make Sweden one of the latest European countries to propose national restrictions ahead of the broader EU legislation. Thu, 30 Jul 2026 22:30:02 +0000
[News] CARICOM moves towards regional framework for cancer The Caribbean Community (CARICOM) is moving towards a regional framework for cancer care after calling for stronger cooperation between members, although questions remain over funding, governance, and implementation. The call followed the 14th Annual Caribbean Association for Oncology and Hematology (CAOH) Scientific Conference, held in Trinidad and Tobago, on July 17–19, 2026. Thu, 30 Jul 2026 22:30:02 +0000
[News] UK–Japan research collaboration for cancers in children and young people On July 28, 2026, organisations from the UK and Japan announced a partnership that will provide funding opportunities for international collaborative clinical trials aimed at developing innovative treatments for cancers affecting children and young people (CYP). Thu, 06 Aug 2026 22:30:02 +0000
[News] 2030 hepatitis elimination targets might be missed in Europe Europe is set to miss the WHO target to eliminate viral hepatitis as a public health threat by 2030 despite progress in screening because of gaps in vaccination and reaching key populations, according to the European Centre for Disease Prevention and Control (ECDC). Thu, 06 Aug 2026 22:30:02 +0000
[News] New liver cancer medicine fast-tracked by UK Government A new medicine for hepatocellular liver cancer has been granted an Innovation Passport through the UK's Innovative Licensing and Access Pathway (ILAP), the Medicines and Healthcare products Regulatory Agency (MHRA) announced last week. Thu, 13 Aug 2026 22:30:01 +0000
[News] Saint Lucia launches national cancer registry The eastern Caribbean island nation of Saint Lucia has launched a national population-based cancer registry, 7 years after first announcing plans to establish one, as it seeks to replace fragmented records and modelled estimates with systematic data on cancer incidence. The registry comes as the country develops a cancer control plan, but its usefulness will depend on complete case reporting, specialist staff, sustained financing, and whether the resulting data influence policy making. Thu, 13 Aug 2026 22:30:02 +0000
[Perspectives] A polycrisis in cancer care: Cuba's system under the oil blockade Cuba's cancer care programme is facing a polycrisis, in which disruptions in energy supply, pharmaceutical access, and technological capacity interact and reinforce one another. The strain is most visible at two of its most resource-intensive nodes: the supply of cytostatic drugs for chemotherapy and the operational readiness of radiotherapy. Both have long been limited by restricted access to pharmaceutical markets, equipment, and spare parts under the decades-long US trade embargo. The oil blockade imposed on Jan 29, 2026 (figure 1), has converted these chronic constraints into an acute systemic breakdown. Fri, 19 Jun 2026 22:30:01 +0000
[Perspectives] Rethinking failure and tolerance in oncology When I received my first chemotherapy tablets, the literature was terrifying: the insert warned against touching the pills or my bodily fluids without gloves. The bag read CAUTION next to a neon yellow biohazard symbol. Shared bathrooms were discouraged. I thought: if this treatment is so dangerous, why am I supposed to ingest it? Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study STRIDE plus lenvatinib plus TACE showed a statistically significant progression-free survival improvement versus TACE. These findings support a STRIDE-based regimen as a potential new treatment option for people with embolisation-eligible HCC; additional follow-up is being conducted for final analysis of overall survival across treatment groups. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial Ivonescimab plus chemotherapy showed a clinically meaningful and statistically significant progression-free survival benefit in patients with EGFR-mutated NSCLC after progression on EGFR-TKI therapy. The clinical benefit and lack of new safety signals of ivonescimab with chemotherapy support the potential for the combination as a new treatment option in this patient population. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial For patients with resected ALK-positive NSCLC, adjuvant alectinib had a manageable safety profile; HRQoL improved and was maintained over 2 years of active treatment. Together with the disease-free survival benefit seen in ALINA, these data support adjuvant alectinib as an important new standard-of-care for patients with resected ALK-positive NSCLC. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial These early results support a response-adapted organ-preservation approach, with LCCRT appearing more effective than SCRT at 12 months. Organ-preservation might also reduce treatment-related toxicity compared with primary TME. Longer follow-up is needed for the prespecified 30-month endpoint and definitive functional and oncological outcomes. Sun, 23 Aug 2026 22:30:02 +0000
[Articles] Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial The combination of ifebemtinib and garsorasib showed promising anticancer activity and manageable safety profile in previously treated patients with KRASG12C-mutated metastatic colorectal cancer. Although the improvement in response rate did not reach statistical significance in the randomised study, these findings support further evaluation of ifebemtinib plus garsorasib in this population. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial SHR-A2102 demonstrated a safety profile consistent with its topoisomerase I inhibitor payload and showed promising activity in patients with various advanced solid tumours who had previously received anti-cancer treatment. A range of active dose was identified in various tumour types. Several trials are ongoing to evaluate SHR-A2102, either as monotherapy or in combination, in advanced solid tumours. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial For patients with high-risk prostate cancer, radiotherapy at a total dose of 80 Gy, in combination with long-term ADT, improved progression-free survival and could be a potential option in this situation. However, given the low number of events, further research is needed to consolidate and confirm the benefit in dose-escalation in prostate cancer-specific survival and overall survival. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial Standardised manual sTIL scoring was reproducible, and digital and AI-based methods showed consistent prognostic stratification and potential for treatment-benefit stratification despite only modest correlation between platforms. AI spatial metrics provided complementary information beyond sTIL density and could support more scalable immune assessment. Future studies are needed to validate these approaches in independent cohorts and to clarify their clinical utility for stratifying contemporary HER2-directed therapies. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study Two cTIL models deployed entirely without retraining or modification provided statistically significant prognostic information and improved risk discrimination compared with clinicopathological variables alone in this large, platform-based, independent validation study. Although cTIL score did not incrementally improve prognostication compared with models combining clinicopathological variables with sTIL score, these findings support the application of cTILs as a reproducible prognostic biomarker, particularly in settings where routine or widespread pathologist assessment is unavailable. Tue, 01 Sep 2026 00:00:00 -0700
[Policy Review] Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus Management of second ipsilateral breast cancer events (iBCEs) remains controversial, and there is a need to collate existing evidence and international guidance on patient selection and local treatment strategies. This project, endorsed by US and European surgical and radiation oncology societies, aimed to gather expert consensus on these issues. A questionnaire on second iBCE local treatment was developed and reviewed by a core group of eight experts, and Delphi methodology was applied over two rounds to 36 panellists, including radiation oncologists, breast surgeons, a plastic surgeon, and medical physicists. Wed, 29 Jul 2026 22:30:02 +0000
[Review] Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group Tumour-infiltrating lymphocytes (TILs) are prognostic and predictive biomarkers in breast cancer. High pre-treatment TILs are associated with a favourable prognosis and improved response to systemic therapies. However, the role of TILs in mediating response to radiotherapy in breast cancer remains underexplored, with scarce clinical evidence to date. In this Review, we present an overview of current evidence and potential mechanisms, highlight opportunities for integrating TILs into radiation oncology trials and clinical practice, and call for standardised TIL reporting to accelerate biomarker-driven individualisation of radiotherapy in breast cancer. Tue, 01 Sep 2026 00:00:00 -0700
[Personal View] Challenges in the use of the European Society for Radiotherapy and Oncology–European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer The oligometastatic disease classification system, developed within the European Society for Radiotherapy and Oncology (ESTRO)–European Organisation for Research and Treatment of Cancer (EORTC) OligoCare project, has been proposed for prognostic stratification and clinical trial design across solid tumours. Its application to ovarian cancer, however, is challenged by two disease-specific features: early and often diffuse peritoneal spread and the difficulty of lesion enumeration when peritoneal deposits are not discretely measurable. Tue, 01 Sep 2026 00:00:00 -0700
|
A systematic review of international/national guidelines for the management of nasopharyngeal carcinoma: Convergence and divergence of recommendations
Fri, 11 Sep 2026 11:16:35 -0700 T‐cell engagers in small cell lung cancer Fri, 11 Sep 2026 00:50:44 -0700 Male survivors of childhood cancer and perceptions of sexual dysfunction risk: A report from the Childhood Cancer Survivor Study Many male survivors do not perceive heightened risks for SD, despite a history of treatment‐related risk factors. Because SD risk is multifactorial, oncology and survivorship providers should prioritize individualized education and counseling to improve survivors’ understanding of their risk on the basis of their treatment history and current health. Fri, 11 Sep 2026 00:42:48 -0700 The evolving role of immunotherapy in ovarian cancer Fri, 11 Sep 2026 00:41:04 -0700 Prevalence of breast, cervical, and colorectal cancer screening among adults according to disability type and difficulty level, United States, 2021 and 2023 Addressing barriers for individuals with self‐care limitations could improve suboptimal screening levels across multiple cancer screenings. Self‐sampling modalities, including stool testing, may mitigate accessibility issues, and warrant further evaluation. Thu, 10 Sep 2026 07:00:07 -0700 Correction to “Breaking barriers: Opt‐out tobacco dependence treatment in oncology care” Wed, 09 Sep 2026 00:32:34 -0700 Elevated risk of ischemic stroke after invasive cancer diagnosis: A nationwide population‐based study The early period after cancer diagnosis represents a critical window of increased IS risk. Incorporating targeted cerebrovascular risk assessment into oncologic care may facilitate earlier identification of high‐risk subgroups and support tailored prevention strategies. Tue, 08 Sep 2026 00:01:30 -0700 Long‐term outcomes and patterns of failure in patients with thymic malignancies treated with surgery and radiation therapy In patients with surgically treated thymic malignancies, tumor invasiveness, especially vascular invasion, was the strongest predictor of recurrence and should guide risk stratification. Failure was predominantly pleural, with rare in‐field recurrence, indicating good local control but a need for better strategies against pleural relapse. Survival benefit from peri‐operative radiation remains uncertain and should be tested prospectively. Thu, 03 Sep 2026 11:12:29 -0700 Issue Information Thu, 03 Sep 2026 11:11:44 -0700 |
||
|
| |||
|
[Editorial] Beyond maximum grade: a decade in the making
The past decade has seen many advances in the treatment of haematological malignancies, particularly with the rise of immunotherapies and CAR T-cell therapies. Other treatments, such as tyrosine kinase inhibitors for chronic myeloid leukaemia, have changed the disease to that of a chronic condition, treated with continuously administered therapies that have unique adverse events over time. With these changes, how adverse events are measured, reported, and the patient's perception of these adverse effects needs to be updated as well. Tue, 01 Sep 2026 00:00:00 -0700
[Comment] Beyond maximum grade: making toxicity count In modern haematology, toxicities often persist long after completion of treatment regimens. Advances in overall survival, alongside the expanded adoption of continuous dosing regimens, immunotherapies, and cellular therapies, have rendered adverse events a lasting burden for patients throughout remission, chronic disease management, and long-term survivorship. Yet the standard Common Terminology Criteria for Adverse Events (CTCAE) maximum grade only records toxicity at its worst point, rather than its persistence, recurrence, cumulative burden, or short-term or long-term effects on daily life. Tue, 01 Sep 2026 00:00:00 -0700
[Correspondence] FAIR(er) treatment of non-anaemic iron deficiency during pregnancy: clarifying the evidence – Authors' reply We thank Ankur Jain for their thoughtful comments regarding our FAIR trial1 and the discussion regarding the prevention of anaemia during pregnancy.2 Our findings show that, among women with non-anaemic iron deficiency diagnosed at the first antenatal care visit, intravenous iron was superior to 30 mg daily oral iron in preventing maternal anaemia. We take the opportunity to address the points raised in the Correspondence. Tue, 01 Sep 2026 00:00:00 -0700
[News] ISTH 2026 Congress Dr Steven McKenzie (Cardeza Foundation for Hematologic Research, Philadelphia, PA, USA) and colleagues presented the ALATHEA trial (NCT05785819) that compared the safety and efficacy of 200 mg intravenous VLX-1005 every 12 h (a small-molecule inhibitor of 12-lipoxygenase) versus placebo in patients with suspected heparin-induced thrombocytopenia undergoing standard-of-care treatment with a direct thrombin inhibitor. 24 patients were randomised 1:1 to the two treatment groups; 22 received study treatment and 17 had confirmed HIT (eight received VLX-1005 and nine placebo). Tue, 01 Sep 2026 00:00:00 -0700
[News] Building stronger blood systems On June 12, 2026, WHO released its latest global report on blood safety and availability, drawing on data from 168 countries. Voluntary unpaid donors now account for 85% of blood donations. Total blood collections increased by 19% from 2013 to 2023 across 132 countries. Nonetheless, governance and oversight remain patchy. 48 countries do not have specific legislation addressing the safety and quality of blood and blood products for transfusion, while 62 countries have not established systems for regular inspection of blood transfusion services. Tue, 01 Sep 2026 00:00:00 -0700
[In Focus] Menstruation in Nepal: tradition, stigma, and transition Nepal, a landlocked country in south Asia bordered by China and India, is known for its geographical, cultural, and religious diversity. It is the only country with a living goddess—The Kumari—a chosen pre-menarcheal girl from Newar community worshipped by all Nepalis, including the head of state. But among this diversity is the belief around menstruation (although differing between region, cast, and culture) that leads to nearly 89% of Hindu women and girls in Nepal to experience some form of menstrual restriction. Mon, 13 Jul 2026 02:30:03 +0000
[In Focus] Reproductive health in Ireland: moving forward as others roll back When politics and reproductive health intersect, women, girls, and people with the potential to menstruate can be substantially impacted, as seen recently in the USA. The devastating effects of undermining and defunding women's health programmes have generated worthy media attention; however, progress in reproductive health is less fêted. As an example, Ireland has emerged as a progressive voice for women's health despite the persistence into the 21st century of highly restrictive, conservative legislation shaped by historical religious influences on society. Mon, 13 Jul 2026 02:30:02 +0000
[In Focus] Living with a bleeding disorder as a woman I was remembering all the times I wanted to talk to my dad to ask him about what was happening to me, but he avoided it every time. He did not want to accept that I also needed special medical care. It hurt me a lot to see my dad suffering because of haemophilia, but it hurt me even more not to feel accepted or seen by him. Mon, 13 Jul 2026 02:30:02 +0000
[Articles] Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial Epcoritamab plus rituximab–lenalidomide showed high activity in first-line treatment for follicular lymphoma, with 95% of patients having a response over 3 years of follow-up, supporting this treatment regimen as a promising approach that warrants further analysis to ascertain its role in this setting. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial The addition of venetoclax to DA-EPOCH-R resulted in excess mortality, prompting early study closure. Robust accrual shows that prospective multicentre trials are feasible in double-hit lymphoma, and the outcomes in the DA-EPOCH-R group serve as a benchmark for future studies. Tue, 01 Sep 2026 00:00:00 -0700
[Articles] Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party We showed that allo-HSCT is an effective and potentially curative treatment option for patients with hepatosplenic T-cell lymphoma; auto-HSCT is frequently followed by relapse and might be only recommended to patients with a complete response and ineligible for allo-HSCT. Thu, 13 Aug 2026 22:30:02 +0000
[Articles] CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study The results of this study showed the feasibility of rapid multicentre decentralised manufacturing and delivery of fresh CAR T-cell therapy in heavily pretreated B-cell non-Hodgkin lymphoma. The phase 2 part of ATALANTA-1 will provide further information on clinical activity and safety. Tue, 01 Sep 2026 00:00:00 -0700
[Series] Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies With more potent and novel treatment options, the number of survivors of haematological malignancies is increasing steadily, which in turn leads to the need for parallel improvements in survivorship monitoring and care. The present paper forms part of The Lancet Haematology Series on adverse event reporting, dedicated to improving adverse event assessment in haematological malignancies. Here, we review current survivorship care practice from a global perspective and conclude that access to long-term care plans is highly heterogeneous, with insufficient adaptation to the specific needs of haematological malignancy survivors treated curatively or non-curatively. Tue, 01 Sep 2026 00:00:00 -0700
[Series] Beyond maximum grade: key regulatory considerations in adverse event reporting The therapeutic landscape of haematological malignancies has evolved rapidly with the introduction of targeted therapies, immunotherapies, and cell-based and gene-based interventions, leading to improved survival and, in some cases, long-term remission or cure. These advances have exposed limitations in traditional approaches to adverse event assessment and reporting. Building on the 2025 Lancet Haematology Series on adverse event reporting, this Series paper examines how proposed improvements in toxicity reporting can be operationalised and integrated into regulatory decision making across clinical trials and real-world settings. Tue, 01 Sep 2026 00:00:00 -0700
[Series] Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers Real-world data are essential for understanding treatment-related toxicities in haematology, but traditional analyses are limited by data access, sharing constraints, and reduced data granularity. Emerging digital health technologies (DHTs), such as electronic patient-reported outcomes and wearable devices, can be used to capture continuous, patient-generated data not reliably captured by current post-marketing toxicity assessments. Artificial intelligence, synthetic data, and digital twins can be used to predict and simulate toxicity at a much larger scale beyond the capacity of traditional methodologies. Tue, 01 Sep 2026 00:00:00 -0700
[Clinical Picture] Concurrent BCR::ABL1 and CBFA2T3::GLIS2 fusions in an adult patient with acute leukaemia A 34-year-old man was admitted to Ruijin Hospital (Shanghai, China) in December, 2024, with acute onset of unexplained high fever and a 1-year history of mild splenomegaly. Laboratory testing showed rapidly progressive leukocytosis with 36% circulating blasts and thrombocytopenia. Abdominal ultrasonography verified splenomegaly, with the spleen measuring 156 mm in length and 58 mm in thickness. Tue, 01 Sep 2026 00:00:00 -0700
|
Time will tell: 5 years of TRANSCEND
Volume 148, Issue 11 September 10 2026 An RNA splicing–translation circuit for hematopoietic fate Volume 148, Issue 11 September 10 2026 NF-κB as a compass for CAR-T fitness in multiple myeloma Volume 148, Issue 11 September 10 2026 WNK1: an atypical kinase vulnerability in T-ALL Volume 148, Issue 11 September 10 2026 When membranes fail: FAP-1 and the mega roots of MF Volume 148, Issue 11 September 10 2026 JAK of all trades: IFN-α hits PV on multiple fronts Volume 148, Issue 11 September 10 2026 Integrin αIIbβ3: more than meets the fibrinogen Volume 148, Issue 11 September 10 2026 Good fences make good neighbors: blood-brain barrier in SCD Volume 148, Issue 11 September 10 2026 A platelet lipid switch that slows clotting Volume 148, Issue 11 September 10 2026 CD4+CD25+FOXP3+ regulatory T cells to protect against graft-versus-host disease Graft-versus-host disease (GVHD) remains a major challenge after allogeneic bone marrow transplantation. Negrin and Meyer review the pathobiology of GVHD, the biology of regulatory immune cells, and the preclinical studies that led to clinical testing of CD4+CD25+FOXP3+ regulatory T cells in allogeneic hematopoietic cell transplantation, culminating in a recent US Food and Drug Administration approval.
Volume 148, Issue 11 September 10 2026 Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of large B-cell lymphoma (LBCL), but long-term follow-up is essential. Abramson et al report 5-year results for relapsed/refractory (R/R) LBCL from TRANSCEND NHL-001, showing durable outcomes with a 5-year overall survival of 38%, comparable to other approved CAR-T products. Although long-term follow-up excluded more than one-third of eligible survivors, these data provide important evidence of CAR-T durability and will help inform treatment decisions in an era of multiple CAR-T and bispecific antibody options.
Volume 148, Issue 11 September 10 2026 Translational regulation of Sf1 integrates alternative splicing and hematopoietic stem cell fate Transition of hematopoietic stem cells (HSCs) from quiescence to lineage commitment requires precise posttranscriptional control, but the role of mRNA isoform regulation is incompletely defined. Liudkovska et al show that translational control of splicing factor 1 (Sf1) coordinates alternative splicing during hematopoietic differentiation, linking Sf1-dependent splicing programs to translation and DNA damage response pathways in hematopoietic stem and progenitor cells. This study underscores the importance of posttranscriptional regulatory mechanisms in the regulation of HSC cell fate.
Volume 148, Issue 11 September 10 2026 Product-intrinsic NF-κB–driven transcriptional programs connote durability of CAR-T response in multiple myeloma Although idecabtagene vicleucel (ide-cel) induces deep responses in relapsed/refractory multiple myeloma, most patients relapse within 1 year. Using single-cell sequencing, Noble et al identified an infusion product transcriptional signature, marked by NF-κB, prosurvival, chemokine/tonic signaling, and higher chimeric antigen receptor (CAR) expression, that is enriched in CAR+ CD4+ T cells and independently associated with improved progression-free and overall survival. These findings suggest that product-intrinsic transcriptional fitness may better predict durable CAR-T activity than current potency assays.
Volume 148, Issue 11 September 10 2026 Inhibition of the atypical kinase WNK1 as a therapeutic strategy in TAL-related T-cell acute lymphoblastic leukemia T-cell acute lymphoblastic leukemia (T-ALL) has a high relapse rate and remains difficult to treat, with few recurrent kinase drivers identified and no approved targeted therapies. Using a multiomics approach, Montanaro et al identified the atypical serine/threonine kinase WNK1 (with no lysine 1) as a dependency in TAL-rearranged T-ALL and show that its inhibition induces mitotic defects. This work supports WNK1 as a promising therapeutic target for this poor-prognosis subgroup.
Volume 148, Issue 11 September 10 2026 FAP-1 loss impairs megakaryocyte demarcation membrane system and platelet function with myelofibrosis-like features Primary myelofibrosis is characterized by dysplastic megakaryocytes with an impaired demarcation membrane system (DMS) and defective proplatelet formation. Chiu et al show that deficiency of Fas-associated phosphatase 1 (FAP-1) disrupts DMS formation, impairing megakaryocyte maturation and platelet function and, with aging, promoting myelofibrosis-like features. Their findings identify FAP-1 as a previously unrecognized regulator of megakaryocyte maturation and provide new insight into how megakaryocyte dysfunction may contribute to the pathogenesis of myelofibrosis.
Volume 148, Issue 11 September 10 2026 Type-I interferon–activated NK cells control polycythemia vera in vivo Although interferon alfa (IFN-α) is an effective treatment for polycythemia vera (PV), its immune-mediated mechanisms remain unclear. Lossa et al show that IFN-α expands CD27+ natural killer (NK) cells in a transgenic mouse model of PV and increases CD56bright NK cells in patients with PV, correlating with molecular response. NK cells, via subsequent tumor necrosis factor α secretion, selectively eliminate JAK2-mutant clones, providing an immune mechanism for the therapeutic effects of IFN-α in PV.
Volume 148, Issue 11 September 10 2026 Reduced platelet formation associated with serine metabolic dysregulation in integrin αIIbβ3–deficient megakaryocytes Volume 148, Issue 11 September 10 2026 Proteomic profiling identifies systemic drivers of blood-brain barrier injury in sickle cell disease Adults with sickle cell disease (SCD) remain at risk for white matter injury and cognitive decline despite modern therapy. Wang et al show that blood-brain barrier (BBB) disruption is common in adults with SCD and is associated with brain microstructural injury. Proteomic analyses link increased BBB permeability to pathways involving immune regulation, extracellular matrix degradation, lipid metabolism, and arginine-proline metabolism, suggesting potential therapeutic avenues.
Volume 148, Issue 11 September 10 2026 Targeting ACKR3/CXCR7 enhances platelet anticoagulant acylcarnitines and modulates procoagulant function Volume 148, Issue 11 September 10 2026 Cuplike nuclei and bimodal CD34 expression in adult KMT2A-rearranged pro-B acute lymphoblastic leukemia Volume 148, Issue 11 September 10 2026 Rowan CM, Pike F, Cooke KR, et al. Assessment of ST2 for risk of death following graft-versus-host disease in the pediatric and adult age groups. Blood. 2020;135(17):1428-1437. Volume 148, Issue 11 September 10 2026 |
Splenic Tropism and Spleen‐Modulated Systemic Inflammation in Acute Plasmodium vivax Malaria
Thu, 10 Sep 2026 21:03:27 -0700 Basophilic Stippling Unmasks Pyrimidine 5′‐Nucleotidase Deficiency in a G6PD‐Deficient Patient Thu, 10 Sep 2026 02:14:34 -0700 The Presence and Percentage of Circulating Nucleated Red Blood Cells Reveal Distinct Characteristics in Adults With Sickle Cell Disease Wed, 09 Sep 2026 21:50:52 -0700 Noninvasive Diagnosis of Splenosis Using Tc‐99m Heat‐Denatured Red Blood Cell Scintigraphy Wed, 09 Sep 2026 21:32:12 -0700 Anticoagulant Therapy and Bleeding‐Related Hospitalizations in Patients With Cancer: A National Cohort Study Mon, 07 Sep 2026 20:59:50 -0700 Obesity‐Related Inflammation Masks Iron Deficiency in US Women Sun, 06 Sep 2026 21:37:12 -0700 Clonally Related Chronic Lymphocytic Leukemia and Malignant Histiocytic Neoplasm (Histiocytic Sarcoma With Overlapping Langerhans Cell Phenotype): Divergent Evolution From a Shared Cell‐Of‐Origin Sat, 05 Sep 2026 01:59:39 -0700 Robustness of Hemophagocytic Lymphohistiocytosis Risk Estimates in CAR T‐Cell Therapy Thu, 03 Sep 2026 22:10:33 -0700 Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma Thu, 03 Sep 2026 06:11:42 -0700 Subphenotypes of Sickle Cell Disease: A Guide to Targeting Treatment? Thu, 03 Sep 2026 06:11:42 -0700 Issue Information Thu, 03 Sep 2026 06:11:42 -0700 Correction to “Impairment of Innate Immunity and Depletion of Vaccine‐Induced Memory B and T Cells in the Absence of the Spleen” Thu, 03 Sep 2026 06:11:42 -0700 Monoclonal Gammopathy of Thrombotic Significance Thu, 03 Sep 2026 06:11:42 -0700 Unique Aspects of Allogeneic Hematopoietic Stem Cell Transplantation in VEXAS Syndrome: One Size Does Not Fit All Thu, 03 Sep 2026 06:11:42 -0700 Undetectable Hydroxyurea in an Untimed Blood Sample Does Not Establish Nonadherence Thu, 03 Sep 2026 06:11:42 -0700 A New Fetal Hemoglobin‐Related Phenotype in Sickle Cell Anemia Thu, 03 Sep 2026 06:11:42 -0700 Luspatercept Induces Significant Improvement in Anemia in Dominant Thalassemia Secondary to Heterozygous STEAP3 and Beta‐Thalassemia Trait Thu, 03 Sep 2026 06:11:42 -0700 Subtotal Versus Total Splenectomy in Children With Sickle Cell Disease: Clinical Outcomes and Splenic Function Assessed by Pocked Red Blood Cell Count Thu, 03 Sep 2026 06:11:42 -0700 The Pitfalls of Categorizing Donor Age: Arbitrary Cutoffs Fail to Predict Survival in Haploidentical HCT Thu, 03 Sep 2026 06:11:42 -0700 Real‐Life Study on Gilteritinib‐Related Infections (GilteRInf): An Italian SEIFEM Study Thu, 03 Sep 2026 06:11:42 -0700 A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST) Thu, 03 Sep 2026 06:11:42 -0700 |
|
|
| |||
|
Stretching a doublet into a triplet for FLT3 AML September 8 2026 - Volume 10, Issue 17 Shuffling the JAKs: playing a new card in chronic GVHD September 8 2026 - Volume 10, Issue 17 When endurance running leads to functional iron deficiency September 8 2026 - Volume 10, Issue 17 Doing more with less in hemophilia B gene therapy September 8 2026 - Volume 10, Issue 17 CAR T before the storm: early consolidation in B-ALL September 8 2026 - Volume 10, Issue 17 American Society of Hematology 2026 guidelines for the diagnosis and management of severe and very severe acquired aplastic anemia September 8 2026 - Volume 10, Issue 17 Myelodysplasia in VEXAS syndrome September 8 2026 - Volume 10, Issue 17 Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML September 8 2026 - Volume 10, Issue 17 Baricitinib for refractory chronic graft-versus-host disease: results of a phase 1/2 study September 8 2026 - Volume 10, Issue 17 A comprehensive multicenter study assessing the impact of abelacimab, asundexian, and milvexian on coagulation assays September 8 2026 - Volume 10, Issue 17 Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma September 8 2026 - Volume 10, Issue 17 EuroNet-PHL-LP1: complete resection or low-dose chemotherapy for pediatric low-risk nodular lymphocyte–predominant Hodgkin lymphoma September 8 2026 - Volume 10, Issue 17 Outcomes of adolescents and young adults with AML treated on pediatric vs adult protocols September 8 2026 - Volume 10, Issue 17 A machine learning–derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL September 8 2026 - Volume 10, Issue 17 Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL September 8 2026 - Volume 10, Issue 17 Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study September 8 2026 - Volume 10, Issue 17 Increased gene therapy efficacy through the use of extended half-life clotting factors September 8 2026 - Volume 10, Issue 17 Single-cell analysis of adaptive NK and CMV-specific T-cell dynamics after allogeneic HSCT September 8 2026 - Volume 10, Issue 17 CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission September 8 2026 - Volume 10, Issue 17 Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL September 8 2026 - Volume 10, Issue 17 Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia September 8 2026 - Volume 10, Issue 17 KIT mutation and AHN-associated oncogenic profiles in systemic mastocytosis with an associated hematological neoplasm September 8 2026 - Volume 10, Issue 17 Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement September 8 2026 - Volume 10, Issue 17 Maintenance therapy and improved relapse-free survival in patients with monoclonal gammopathy of renal significance September 8 2026 - Volume 10, Issue 17 Long-distance trail running induces functional iron deficiency driven by inflammation September 8 2026 - Volume 10, Issue 17 Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias September 8 2026 - Volume 10, Issue 17 Cardiovascular risk scores estimate arterial thrombotic risk in aging adults with hemophilia in the ADVANCE Japan cohort September 8 2026 - Volume 10, Issue 17 Mutational profiling links biologically relevant variants to multisystemic Rosai-Dorfman disease September 8 2026 - Volume 10, Issue 17 TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma September 8 2026 - Volume 10, Issue 17 Secondary anticoagulation prophylaxis for children with antiphospholipid syndrome: a systematic review and meta-analysis September 8 2026 - Volume 10, Issue 17 Class 3 MAP2K1 mutations associate with relapse and multiple treatment lines in multisystem Langerhans cell histiocytosis September 8 2026 - Volume 10, Issue 17 Minimal residual disease by high-throughput sequencing in standard risk–favorable pediatric B-lymphoblastic leukemia September 8 2026 - Volume 10, Issue 17 Complementary targeted constructs factor XI/XIa inhibition September 8 2026 - Volume 10, Issue 17 E-lesion or stage IV disease? An ongoing unsettled issue in pediatric Hodgkin lymphoma September 8 2026 - Volume 10, Issue 17 Revisiting KIR restriction and CD94 expression in diagnostic criteria for NK–large granular lymphocytic leukemia September 8 2026 - Volume 10, Issue 17 Immunophenotyping challenges in the diagnosis of NK-LGLL September 8 2026 - Volume 10, Issue 17 Diagnosis of NK–large granular lymphocytic leukemia September 8 2026 - Volume 10, Issue 17 Heestermans R, Olsen C, Ameli S, et al. Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma. Blood Adv. 2025;9(16):4306-4310. September 8 2026 - Volume 10, Issue 17 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Complete Revascularization Guided by Functional Coronary Angiography in STEMI
29 Aug 2026 Outbreak of Severe Methemoglobinemia during Maritime Migration 9 Sep 2026 Treatment Decisions in Multiple Myeloma 9 Sep 2026 Zongertinib in HER2-Mutant Non–Small-Cell Lung Cancer 9 Sep 2026 Ensitrelvir for Covid-19 Postexposure Prophylaxis 9 Sep 2026 Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism 9 Sep 2026 Neuroinvasive Trichodysplasia Spinulosa–Associated Polyomavirus Infection 9 Sep 2026 Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy 9 Sep 2026 FDA’s New Framework for Psychedelic Drugs 9 Sep 2026 Advancing Gene Editing for Children with Hemoglobinopathies 9 Sep 2026 A Step Forward — Obinutuzumab for Membranous Nephropathy 9 Sep 2026 Grey Turner’s Sign 9 Sep 2026 Adie Tonic Pupil 5 Sep 2026 Case 25-2026: A 65-Year-Old Man with Fever and Rash 9 Sep 2026 The Long Shadow of Bedlam 5 Sep 2026 AI-Based Translation of Discharge Instructions — Aligning Policy with Practice 5 Sep 2026 The Future of the USPSTF and Evidence-Based Recommendations 5 Sep 2026 When Fear Became the Barrier to Care — Lessons of a Clinical Rapid Response during Operation Metro Surge 5 Sep 2026 Immediate Ambulatory Electrocardiographic Monitoring in Syncope 31 Aug 2026 Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism 31 Aug 2026 Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy 28 Aug 2026 Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis 28 Aug 2026 Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk 28 Aug 2026 Eplontersen for Transthyretin Amyloid Cardiomyopathy 28 Aug 2026 Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation 30 Aug 2026 Tricuspid-Valve Intervention in Heart Failure 30 Aug 2026 Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension 30 Aug 2026 Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults 29 Aug 2026 Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients 29 Aug 2026 Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain 29 Aug 2026 Prasugrel versus Ticagrelor in Acute Coronary Syndromes 29 Aug 2026 Prevalence of Silent Atherosclerosis across Adult Life 29 Aug 2026 Tozorakimab to Prevent COPD Exacerbations 8 Sep 2026 Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials 9 Sep 2026 Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event 29 Aug 2026 Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI 29 Aug 2026 Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy 12 Sep 2026 Reengineering Coagulation with a Bispecific Antibody 9 Sep 2026 The Legacy of Orexin (Hypocretin) Research in Narcolepsy and Beyond 9 Sep 2026 Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310 28 Aug 2026 Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke 28 Aug 2026 The Emerging Role of Treatment Policy Implementation Trials in Acute Coronary Syndrome 29 Aug 2026 Targeted Treatment for Narcolepsy Type 1 9 Sep 2026 Celiac-Artery Dissection 12 Sep 2026 Honoring the Legacy of the HIV Epidemic 12 Sep 2026 A New Approach for the Indian Health Service — Academic Physician Staffing 12 Sep 2026 The Epstein Files Transparency Act and the Health of Trafficked Children 12 Sep 2026 Artificial Intelligence and the Future of the Clinical Workforce 12 Sep 2026 |
|
|
| |||
|
|
Neoadjuvant chemotherapy in women with triple-negative breast cancer: real world results from Western Kenya
Volume 31, Issue 10, October 2026, oyag325 Clinical outcomes of HIF-2α inhibition in Von Hippel–Lindau disease: a multicenter real-world study Volume 31, Issue 10, October 2026, oyag331 Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programme Volume 31, Issue 10, October 2026, oyag341 |
Being Artificially Intelligent September 2026: 69(9):2223-2225 How Much Does It Cost to Become a Colorectal Surgeon? A Cost Comparison of Training in the United States, Australia and New Zealand, and the United Kingdom September 2026: 69(9):2226-2229 Artificial Intelligence for Colorectal Surgeons—Part I: Foundations and Clinical and Educational Applications September 2026: 69(9):2230-2240 Herrmann and Desfosses, the 2 Men “Behind the Anal Glands”: A Brief Account of a Notable Page in the History of Proctology September 2026: 69(9):2241-2247 Managing Reach Limitations in Left-Sided Colectomy September 2026: 69(9):2248-2251 Expert Commentary on Managing Reach in Colectomy: Achieving a Tension-Free Anastomosis September 2026: 69(9):2252-2253 Oncologic Outcomes of Robot-Assisted Upfront Surgery Using a Fascia-Guided Total Mesorectal Excision Strategy for T3 Rectal Cancer September 2026: 69(9):2254-2265 Risk Factors for Small-Bowel Crohn’s Disease Recurrence After Total Proctocolectomy September 2026: 69(9):2266-2272 Sexual Distress Is Common in Long-term Follow-up After Pelvic Pouch for Ulcerative Colitis: A Cross-Sectional Study September 2026: 69(9):2273-2282 End-to-Side Ileocolonic Anastomosis After Ileocecectomy for Crohn’s Disease Is a Safe Option With Low Recurrence September 2026: 69(9):2283-2290 Quadratus Lumborum Block During Minimally Invasive Colorectal Surgery: A Tool for Enhanced Recovery September 2026: 69(9):2291-2300 Risk of Metabolic Disease After Right- Versus Left-Sided Colectomy for Colon Cancer: A Nationwide Cohort Study September 2026: 69(9):2301-2311 Cost-Effectiveness of Pelvic Floor Reconstruction Using Biological Mesh After Extralevator Abdominoperineal Resection for Rectal Cancer September 2026: 69(9):2312-2320 Patient-Level Socioecological Comorbidities and Time to Initiation of Curative-Intent Treatment for Colorectal Cancer September 2026: 69(9):2321-2331 Selected Abstracts September 2026: 69(9):2332-2336 Managing Reach Problems in Pouch Surgery: Lengthening Maneuvers and S-Pouch Creation September 2026: 69(9):2337-2337 Artificial Intelligence–Assisted Anatomical Recognition System-Guided Robotic Total Mesorectal Excision and Autonomic Nerve Preservation for Rectal Neuroendocrine Tumor September 2026: 69(9):2338-2338 Simultaneous Application of Robotic Surgery and Transanal Minimally Invasive Surgery Platform in the Context of Sphincter Preservation, Stepwise Description September 2026: 69(9):2339-2339 Robotic Lateral-to-Medial Left Colon Dissection: A Technical Approach for Total Mesorectal Excision September 2026: 69(9):2340-2342 Single-Port Robotic Transstomal End Colostomy Resection and Closure September 2026: 69(9):2343-2344 |
|
|
| |||
|
Biomarker Guides Treatment Sequencing, Predicts Outcomes in BRAF-Mutated Metastatic Melanoma
Using a blood test to track thymidine kinase activity may help determine optimal first-line treatment for patients with BRAF V600–mutated metastatic melanoma, according to findings published in Clinical Cancer Research. Monday, August 31, 2026 12:00 PM High-Dose Vitamin D3 Does Not Improve PFS in Metastatic Colorectal Cancer Adding high-dose vitamin D3 to standard chemotherapy plus bevacizumab did not improve progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer (mCRC), according to results from the phase III SOLARIS trial led by Kimmie Ng, MD, MPH, and colleagues and... Additional Safety Analysis of DESTINY-Breast05: What Did It Show? An additional safety analysis of the global phase III DESTINY-Breast05 trial evaluating the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has further established the pulmonary safety profile of T-DXd with radiotherapy, according to Michael Untch, MD, PhD, of Helios... FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia Today, the U.S. Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft (Besremi) for the treatment of adults with essential thrombocythemia, making it the first new FDA-approved treatment for essential thrombocythemia in nearly 3 decades. Ropeginterferon alfa-2b-njft has been... Monday, August 31, 2026 12:00 PM FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera On August 28, the U.S. Food and Drug Administration (FDA) approved rusfertide (Mimrylo) for the treatment of erythrocytosis in adults with polycythemia vera (PV). Rusfertide is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to... Monday, August 31, 2026 11:05 AM The Mid-Career Oncologist in LMIC Regions: Navigating Disparities, Avoiding Burnout, and Delivering Optimal Care Large Multicenter Study Evaluates LITT for Primary and Metastatic Brain Tumors According to findings from the prospective multicenter LAANTERN study reported by Leuthardt et al in the Journal of Clinical Oncology, laser interstitial thermal therapy (LITT) may offer a minimally invasive cytoreductive option for selected patients with primary and metastatic brain tumors, with... Tissue-Free ctDNA Assay May Help Identify Recurrence Risk in Early Triple-Negative Breast Cancer A tissue-free circulating tumor DNA (ctDNA) assay was strongly prognostic for recurrence in patients treated for triple-negative breast cancer and provided a lead time to recurrence comparable to that of a multivariant tumor-informed assay, according to findings from a prognostic study published by ... Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer Researchers have reported that a chemotherapy-free combination of four targeted therapies showed encouraging results in patients with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer, offering a potential first-line treatment option that may be more convenient for some... Friday, August 28, 2026 10:00 AM In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles A comparative study of the cancer clinical trial portfolios supported by federal funding vs industry funding reveals they have distinct, interdependent roles in cancer research. The findings were published by Unger et al in JAMA Oncology. Friday, August 28, 2026 10:00 AM cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions A blood-based assay combining cell-free DNA (cfDNA) fragmentomics with droplet digital PCR–based methylation analysis improved detection of early-stage colorectal cancer (CRC) and precancerous lesions, according to findings presented at the 2026 ASCO Breakthrough meeting in Singapore. Cleveland Clinic to Host Second Annual AI Summit for Health-Care Professionals AI is one of the most transformative technological advancements of our time, poised to revolutionize every aspect of our lives, including health care. On August 28, 2026, Cleveland Clinic in collaboration with the College of Healthcare Information Management Executives (CHIME), will host the Second ... Thursday, August 20, 2026 10:30 AM Cleveland Clinic President Discusses Friday’s AI Summit for Health-Care Professionals Artificial intelligence (AI) is one of the most transformative technological advancements of our time, poised to revolutionize every aspect of our lives, including health care. Wednesday, August 26, 2026 3:41 PM ASTRO Updates Guideline on Radiation Therapy for Pancreatic Cancer An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer. The guideline updates ASTRO’s 2019 recommendations to reflect recent clinical trials that... Thursday, August 13, 2026 11:12 AM ASCO Remembers Dr. Harold P. Freeman, Preeminent Health Equity Expert and Pioneer of Patient Navigation WashU Medicine Appoints New Chief of Head and Neck Surgery Andrés M. Bur, MD, FACS, has been named Chief of the Division of Head and Neck Surgery in the Department of Otolaryngology–Head & Neck Surgery at WashU Medicine and Co-Director of the Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, based at Barnes-Jewish... Thursday, August 27, 2026 10:52 AM Colorectal Cancer May Cause Peripheral Neuropathy Before Treatment, Preclinical Study Finds Colorectal cancer may result in tumor-related inflammation that damages peripheral nerves before even starting cancer treatment, according to preclinical findings published in Nature Communications. This damage may be the reason why colorectal cancer survivors are more likely to develop peripheral... Wednesday, August 26, 2026 12:00 PM Expanded EHR Data May Improve Prediction of Early Adverse Events After AML Induction Chemotherapy Patients with acute myeloid leukemia (AML) frequently experienced unplanned hospital readmission or death within 30 days after discharge following induction chemotherapy, according to findings reported by Chae et al in JCO Clinical Cancer Informatics. The investigators found that incorporating... Prostate Cancer: NRG-GU005 Defines Trade-Offs Between SBRT and Moderately Hypofractionated IMRT In the international phase III NRG-GU005 trial, stereotactic body radiotherapy (SBRT) improved bowel-related quality of life vs moderately hypofractionated intensity-modulated radiotherapy (IMRT) in patients with favorable intermediate-risk prostate cancer. However, Ellis et al reported in JAMA... Dr. Gary R. Morrow, a Pioneer in Cancer Research, Dies at 82 FDA Approves Zanidatamab Combination Regimens for HER2-Positive Gastric, GEJ, or Esophageal Cancer On August 25, 2026, the U.S. Food and Drug Administration (FDA) approved zanidatamab-hrii (Ziihera) for two indications, including: Tuesday, August 25, 2026 1:00 PM ASCO Remembers Supportive Care and Symptom Management Pioneer Gary R. Morrow, PhD, MS FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma On August 26, the U.S. Food and Drug Administration (FDA) approved daraxonrasib (Rasonque), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Wednesday, August 26, 2026 3:02 PM Research Finds Supercentenarians Have an Abundance of Cancer-Killing Immune Cells The human immune system has specialized cells called CD4 cytotoxic T lymphocytes (CD4 CTLs), which have been shown to kill tumor cells in some cancers. These cells multiply in a process called clonal expansion to help fight infection. In a study published by Hashimoto in Cell Reports, researchers... Wednesday, August 26, 2026 11:47 AM Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer Metabolic abnormalities were frequently documented during the first year after men with prostate cancer began concurrent androgen-deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI), according to a large retrospective cohort study led by Amy L. Shaver, PhD, PharmD, MPH, and... Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds Adults who have survived Hodgkin lymphoma for at least 5 years may face significantly elevated long-term health risks and cancer and noncancer mortality, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. The retrospective population-based study,... Monday, August 24, 2026 11:12 AM |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
Publisher Correction: Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology
Publisher Correction: Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology Fri, 11 Sep 2026 00:00:00 -0700 Liver resection improves survival in patients with locally advanced HCC Liver resection improves survival in patients with locally advanced HCC Mon, 07 Sep 2026 00:00:00 -0700 Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology The development of diverse immunotherapeutic modalities has revolutionized the treatment of cancer but the effectiveness of these therapies remains restricted by fundamental mechanistic limitations relating to the generation of tumour-specific T cells, and their activation and/or access into the tumour microenvironment. In this Perspective, the authors position oncolytic viruses as a foundational immuno-oncology platform for systemic immune reprogramming to simultaneously overcome these availability, activation and admission barriers, and delineate four pillars for the development of a new generation of oncolytic virotherapies. Thu, 03 Sep 2026 00:00:00 -0700 Belzutifan plus lenvatinib delays disease progression in advanced-stage RCC Belzutifan plus lenvatinib delays disease progression in advanced-stage RCC Thu, 27 Aug 2026 00:00:00 -0700 Global cancer statistics 2024: translating epidemiological trends into priorities for healthcare systems The global cancer burden is projected to rise substantially in the coming decades, driven largely by population growth and ageing. Yet cancer patterns and outcomes vary widely across regions, reflecting differences in exposures, healthcare capacity and access to care. Translating these evolving epidemiological patterns into effective and equitable cancer-control strategies is increasingly urgent. Wed, 26 Aug 2026 00:00:00 -0700 Exploring the landscape of targetable alterations in patients with glioblastoma Despite considerable progress in other cancer types, progress with the development of targeted therapies for patients with glioblastoma has remained limited, despite considerable research effort. In this Review, the authors summarize the various attempts to develop effective targeted therapies for patients with glioblastoma, including some of the challenges that have likely impaired progress thus far. The authors also highlight novel therapies, clinical trial designs and research directions that have been informed by the shortcomings of previous research efforts, all of which might eventually lead to improved outcomes for patients. Wed, 19 Aug 2026 00:00:00 -0700 Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma The phase III FIGHT-302 trial demonstrated that the FGFR inhibitor pemigatinib improves progression-free survival and response rates versus first-line chemotherapy in patients with advanced-stage FGFR2-rearranged cholangiocarcinoma. However, the trial accrued slowly and closed early after chemoimmunotherapy became the new standard of care. FIGHT-302, alongside two similarly terminated trials, highlights the need for innovative trial designs and flexible regulatory frameworks to evaluate therapies in rare, biomarker-defined populations. Wed, 12 Aug 2026 00:00:00 -0700 How positive was PROTEUS? Reconsidering success when most patients never reach no evidence of disease PROTEUS met its amended co-primary end points but should not be interpreted as practice changing. The trial compared two experimental strategies rather than the current standard of care, relied on an unvalidated approach (prostate-specific membrane antigen-PET) for assessments of metastasis-free survival, demonstrated minimal absolute benefit with increased toxicity and lacks both mature overall survival data and sufficient data on patient-reported outcomes to support adoption. Tue, 11 Aug 2026 00:00:00 -0700 |
|
|
| |||
|
Prognostic significance of DNA damage response-related markers in esophageal squamous cell carcinoma using machine learning approaches
Vol 17, No 4 (August 31, 2026): The association between coffee consumption and esophageal cancer risk: a systematic review and meta-analysis of current observational evidence Vol 17, No 4 (August 31, 2026): FANCI promotes esophageal squamous cell carcinoma progression and cell cycle regulation and interacts with FANCD2 Vol 17, No 4 (August 31, 2026): Human epidermal growth factor receptor 2 expression loss after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma: a retrospective study Vol 17, No 4 (August 31, 2026): Efficacy and safety of sintilimab-based neoadjuvant regimens in patients with resectable gastric or gastroesophageal junction adenocarcinoma: a single-arm systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Prediction-model development and temporal validation for six-month cancer-specific mortality in de novo metastatic gastroesophageal junction adenocarcinoma: a SEER-based study Vol 17, No 4 (August 31, 2026): Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study Vol 17, No 4 (August 31, 2026): Nodal status and advanced clinical stage as determinants of response and survival after induction chemoradiotherapy in esophageal and gastroesophageal junction cancer: a single-centre retrospective cohort study Vol 17, No 4 (August 31, 2026): Screening of molecular biomarkers ASPN and LBH and construction of a prediction nomogram for the progression of esophagogastric junction adenocarcinoma Vol 17, No 4 (August 31, 2026): Non-structural maintenance of chromosome condensin I complex subunit H knockdown suppresses malignant progression of esophageal squamous cell carcinoma via the Wnt/β-catenin signaling pathway Vol 17, No 4 (August 31, 2026): The prognosis of patients with gastrointestinal stromal tumors harboring the KIT exon 11 mutation: a retrospective cohort study Vol 17, No 4 (August 31, 2026): Cuproplasia-associated LOXL2 cooperates with Helicobacter pylori infection to promote gastric cancer progression via the FAK/Src signaling axis Vol 17, No 4 (August 31, 2026): Development and validation of a nomogram for the non-invasive prediction of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma: an 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based study Vol 17, No 4 (August 31, 2026): Non-invasive prediction of occult peritoneal metastasis (OPM) in gastric cancer using logistic regression and random forest integrative models with CT radiomics and clinical parameters: machine learning prediction of gastric OPM Vol 17, No 4 (August 31, 2026): Helicobacter pylori-induced cystathionine-γ-lyase drives redox imbalance and metabolic remodeling in gastric cancer Vol 17, No 4 (August 31, 2026): Development of a postoperative risk scoring tool for elderly patients with early gastric cancer: an exploratory prognostic score derivation study Vol 17, No 4 (August 31, 2026): Increased expression of Ribonucleic acid export 1 (RAE1) gene promotes gastric carcinogenesis and is associated with Hippo signaling pathway Vol 17, No 4 (August 31, 2026): Impact of spatial distribution of M2 macrophages on prognosis and neoadjuvant chemotherapy resistance in gastric cancer Vol 17, No 4 (August 31, 2026): Distinct metastatic patterns and survival outcomes in intestinal- versus diffuse-type gastric cancer: a SEER-based propensity score-matched analysis Vol 17, No 4 (August 31, 2026): Clinical efficacy and safety of apatinib plus S-1 combined with oxaliplatin (SOX) in postoperative stage III gastric cancer patients with high VEGFR-2 expression Vol 17, No 4 (August 31, 2026): A predictive nomogram model for overall survival in obstructive colorectal cancer based on clinical and laboratory indicators Vol 17, No 4 (August 31, 2026): Trajectory identification of high-risk subgroups after colorectal cancer surgery in patients with minimal residual disease: a single-center longitudinal study Vol 17, No 4 (August 31, 2026): Histopathological subtypes independently predict survival in ampullary carcinoma: a contemporary SEER nomogram study Vol 17, No 4 (August 31, 2026): Sphingosine-1-phosphate induces angiogenesis via the activating STAT3 signaling pathway to drive colorectal cancer progression Vol 17, No 4 (August 31, 2026): Artemisinin inhibits colorectal cancer progression via the FAM83A-AS1/HIF-1α axis Vol 17, No 4 (August 31, 2026): Metabolic-cell-death gene trio predicts survival and cuproptosis sensitivity in colorectal cancer Vol 17, No 4 (August 31, 2026): Real-world efficacy and safety of fruquintinib plus PD-1 inhibitors with or without radiotherapy in refractory metastatic colorectal cancer: a single-center retrospective cohort study Vol 17, No 4 (August 31, 2026): Association between metabolic dysfunction-associated steatotic liver disease and risk of early-onset advanced colorectal neoplasia: a systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): MS4A3 as a potential prognostic biomarker for colon cancer: integrated analysis of expression patterns and immune cell infiltration Vol 17, No 4 (August 31, 2026): Radiomic prediction of early progression at 2 years post-treatment in patients with resectable rectal cancer based on rectal tumor and mesentery characteristics: a two-center study Vol 17, No 4 (August 31, 2026): Prognostic significance of lymphovascular invasion in colorectal mucinous adenocarcinoma after curative resection: a nationwide multi-center retrospective cohort study Vol 17, No 4 (August 31, 2026): A study on screening of postoperative chemotherapy beneficial populations in stage II colorectal cancer based on diffusion weighted imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography Vol 17, No 4 (August 31, 2026): Prognostic value of genes associated with metastasis and propionate metabolism in rectal cancer Vol 17, No 4 (August 31, 2026): Global, regional, and national burden of colorectal cancer attributable to modifiable risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Vol 17, No 4 (August 31, 2026): Prognostic impact of mucinous adenocarcinoma after curative surgery for stage I–III colorectal cancer: a large population-based cohort study Vol 17, No 4 (August 31, 2026): Comparative analysis of outcomes and sociodemographic factors in early- and late-onset colorectal cancer hospitalizations Vol 17, No 4 (August 31, 2026): Modifiable risk factors contributing to the rising incidence of early-onset colorectal cancer in the United States over three decades: a Global Burden of Disease analysis Vol 17, No 4 (August 31, 2026): Establishment of a chemoradio-resistance colorectal cancer cell model and its changes in biological behavior Vol 17, No 4 (August 31, 2026): Prediction of histological response by PET-CT after 2 weeks of neoadjuvant chemo-radiotherapy for rectal cancer: a prospective clinical trial Vol 17, No 4 (August 31, 2026): Landscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy Vol 17, No 4 (August 31, 2026): Development and preliminary validation of plasma cell-free DNA methylation-based diagnostic prediction model for colorectal cancer detection Vol 17, No 4 (August 31, 2026): Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial Vol 17, No 4 (August 31, 2026): Application value of dual-phase cone-beam computed tomography during hepatic arteriography in the detection of ≤2 cm hypervascular hepatocellular carcinoma and its feeding arteries Vol 17, No 4 (August 31, 2026): Development and validation of a novel nomogram for predicting long-term survival in gallbladder cancer: a large population-based study using the SEER database Vol 17, No 4 (August 31, 2026): Development and validation of prognostic nomograms for intrahepatic cholangiocarcinoma with concomitant hepatolithiasis after radical resection Vol 17, No 4 (August 31, 2026): Metabolic burden but not metabolic dysfunction-associated steatotic liver disease affects the prognosis of patients with hepatocellular carcinoma after hepatectomy: a retrospective cohort study Vol 17, No 4 (August 31, 2026): Global impact of hepatitis B vaccination on the risk of hepatocellular carcinoma: a systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Immunological characteristics of calmodulin-related genes in hepatocellular carcinoma and their potential for prognostic prediction and diagnostic applications Vol 17, No 4 (August 31, 2026): Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis Vol 17, No 4 (August 31, 2026): Relationships among slow diffusion coefficient and diffusion-derived ‘vessel density’ signal features, Gadoxetate delayed enhancement, tumor size, tumor grading, and patient survival: an exploratory study of mass-forming intrahepatic cholangiocarcinoma Vol 17, No 4 (August 31, 2026): Construction of molecular signatures based on the co-expression network of NECSO-related gene TRPM4 and its prognostic value in hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): Organ-specific response to atezolizumab + bevacizumab combination therapy for unresectable hepatocellular carcinoma with extrahepatic metastases: a retrospective cohort study Vol 17, No 4 (August 31, 2026): A practical nomogram for predicting survival in patients with extrahepatic cholangiocarcinoma: a population-based cohort study Vol 17, No 4 (August 31, 2026): SLC25A45 as a prognostic biomarker promotes malignant progression via mutant p53 in hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): A novel glutamine metabolism-based classification system for characterizing the heterogeneity of hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): A CFH- and SPINT2-based prognostic signature for cholangiocarcinoma Vol 17, No 4 (August 31, 2026): Evolving burden of pancreatic cancer in the Middle East and North Africa Region, 1990–2023: an analysis based on the Global Burden of Disease Study 2023 Vol 17, No 4 (August 31, 2026): Association between preoperative statin use and survival after pylorus-preserving pancreaticoduodenectomy for pancreatic or periampullary cancer: a propensity score-matched cohort study Vol 17, No 4 (August 31, 2026): Development and validation of a nomogram based on three-dimensional quantitative parameters from dual-layer detector spectral computed tomography for predicting treatment response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma Vol 17, No 4 (August 31, 2026): Chronic psychological stress and gastric cancer: bidirectional associations, biological mechanisms, and clinical implications—a narrative review Vol 17, No 4 (August 31, 2026): MNAT1 in gastrointestinal cancers: mechanistic insights and therapeutic strategies—a narrative review Vol 17, No 4 (August 31, 2026): Impacts of neoadjuvant therapy on subsequent surgical difficulty, safety, and outcomes in locally advanced rectal cancer: a narrative review Vol 17, No 4 (August 31, 2026): From clinical insight to trial design: advancing circulating tumor DNA-informed care in pancreatic cancer Vol 17, No 4 (August 31, 2026): Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial Vol 17, No 4 (August 31, 2026): Neuroendocrine tumors of unknown primary: a case report and review of tumors with gastroenteropancreatic features Vol 17, No 4 (August 31, 2026): Diagnostic biopsy-to-treatment interval and risk of recurrence in localized pancreatic ductal adenocarcinoma: every week counts Vol 17, No 4 (August 31, 2026): Non-operative management of rectal adenocarcinoma in a safety-net system: a decade of real-world outcomes outside watch-and-wait eligibility Vol 17, No 4 (August 31, 2026): Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Prognostic role of resting heart rate in patients with colorectal cancer Vol 17, No 4 (August 31, 2026): DNA-dependent protein kinase inhibition as a radiosensitizer in rectal cancer: toxicity must be evaluated in the context of organ preservation Vol 17, No 4 (August 31, 2026): Persistent FGFR pathway dependence: where does tinengotinib fit after FGFR inhibitor therapy in advanced cholangiocarcinoma? Vol 17, No 4 (August 31, 2026): Optimizing hepatocellular carcinoma screening in the era of metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease: time to lower the alpha-fetoprotein threshold Vol 17, No 4 (August 31, 2026): Beyond trastuzumab: redefining first-line HER2-positive gastroesophageal cancer with bispecific HER2 targeting Vol 17, No 4 (August 31, 2026): Identifying actionable targets: predicting imatinib nonadherence in patients with gastrointestinal stromal tumors Vol 17, No 4 (August 31, 2026): Therapeutic drug-monitoring-guided desensitization for severe imatinib-associated rash Vol 17, No 4 (August 31, 2026): Endoscopic ultrasonography ablation for small pancreatic neuroendocrine tumors Vol 17, No 4 (August 31, 2026): Extending the utility of anti-EGFR therapy in metastatic colorectal cancer Vol 17, No 4 (August 31, 2026): Cadonilimab plus chemotherapy in PD-L1-low gastroesophageal cancer: a bispecific opportunity? Vol 17, No 4 (August 31, 2026): Ferroptosis in gastrointestinal stromal tumors Vol 17, No 4 (August 31, 2026): Erratum: Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes Vol 17, No 4 (August 31, 2026): |
|
||
|
| |||
|
Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone
Annals of Internal Medicine, Volume 179, Issue 8, Page 1073-1084, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Prolonged Short Sleep and Its Effect on Body Weight and Composition Annals of Internal Medicine, Volume 179, Issue 8, Page 1085-1093, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Performance of Lung Cancer Risk Prediction Models in Different Racial and Ethnic Groups in the United States: Results From the Lung Cancer Cohort Consortium Annals of Internal Medicine, Volume 179, Issue 8, Page 1094-1106, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes Annals of Internal Medicine, Volume 179, Issue 8, Page 1107-1116, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Comparative Effectiveness of Carvedilol Versus Other Nonselective β-Blockers in Cirrhosis Annals of Internal Medicine, Volume 179, Issue 8, Page 1117-1127, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes Annals of Internal Medicine, Volume 179, Issue 8, Page 1128-1139, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 8, Page 1140-1155, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 8, Page 1156-1168, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Reporting Interest-Holder Engagement in Practice Guidelines: The RIGHT-MuSE Checklist Annals of Internal Medicine, Volume 179, Issue 8, Page 1169-1176, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026) Annals of Internal Medicine, Volume 179, Issue 8, Page 1177-1185, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Visual Guideline - Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Visual Clinical Guideline From the American College of Physicians (April 2026) Annals of Internal Medicine, Volume 179, Issue 8, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 How Would You Manage Perioperative Cardiovascular Risk for Noncardiac Surgery in This Patient With Complex Comorbidity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center Annals of Internal Medicine, Volume 179, Issue 8, Page 1186-1196, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Care of Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists Annals of Internal Medicine, Volume 179, Issue 8, Page 1197-1198, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Prior Authorization and Clinical Authority: Time to Recalibrate? Annals of Internal Medicine, Volume 179, Issue 8, Page 1199-1200, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Revitalizing Primary Care Internal Medicine: Addressing the Hidden Curriculum Annals of Internal Medicine, Volume 179, Issue 8, Page 1201-1202, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Treating Obesity With Pharmacotherapy: Making Sense of the Evolving Science When Data Are Vast but Direct Comparative Evidence Is Sparse Annals of Internal Medicine, Volume 179, Issue 8, Page 1203-1205, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Dear Resident Mother Annals of Internal Medicine, Volume 179, Issue 8, Page 1206-1207, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Giving Up Annals of Internal Medicine, Volume 179, Issue 8, Page 1208-1209, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Identifying Meaningful Patient Savings on Generics: Direct-to-Consumer Prices Versus Commercial Insurance Cost Sharing Annals of Internal Medicine, Volume 179, Issue 8, Page 1210-1212, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 National Prevalence of Clinical Obesity by BMI Class: A National Cross-Sectional Study Annals of Internal Medicine, Volume 179, Issue 8, Page 1212-1215, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets Annals of Internal Medicine, Volume 179, Issue 8, Page 1215-1216, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets Annals of Internal Medicine, Volume 179, Issue 8, Page 1216-1217, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 Effect of Systolic Blood Pressure Measurement Error on the Cost-Effectiveness of Intensive Blood Pressure Targets Annals of Internal Medicine, Volume 179, Issue 8, Page 1217-1217, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 The Effect of Weight Loss Before In Vitro Fertilization on Reproductive Outcomes in Women With Obesity Annals of Internal Medicine, Volume 179, Issue 8, Page 1217-1218, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 The Effect of Weight Loss Before In Vitro Fertilization on Reproductive Outcomes in Women With Obesity Annals of Internal Medicine, Volume 179, Issue 8, Page 1218-1218, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 The Effect of Weight Loss Before In Vitro Fertilization on Reproductive Outcomes in Women With Obesity Annals of Internal Medicine, Volume 179, Issue 8, Page 1218-1219, August 2026. <br/> Tue, 30 Jun 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
Disc sets up polycythemia vera challenge but Silence maintains lead
The polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the FDA’s approval last month for Mimrylo.
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug The enrollment pause comes after BHV-7000 failed to show efficacy in a midstage depression trial late last year. The news is another regulatory hit for Biohaven after the FDA declined to approve its spinocerebellar ataxia treatment in November 2025.
Tyra shares slip as bladder cancer responses fall short of investor expectations Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for non-muscle invasive bladder cancer.
BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’ Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with an upcoming multiple myeloma CAR T therapy from Gilead Sciences, according to BMO Capital Markets.
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s amylin and calcitonin receptor agonist ACCG-2671 showed “impressive” target engagement in a Phase 1 trial of healthy volunteers, according to Leerink Partners.
Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data Mosliciguat, being developed by the Roivant Sciences subsidiary Pulmovant, ‘significantly exceeded expectations’ in reducing pulmonary vascular resistance, according to analysts, and is progressing to a late-stage study.
RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall response rate and overall survival of 16 months.
GSK to launch Phase 3 trial for mRNA-based flu vaccine amid resurgence for the modality GSK’s vaccine—which targets two primary flu antigens—elicited higher immune responses in both younger and older adults in a mid-stage study. The Phase 3 launch, planned for September, follows the FDA’s recent approval for Moderna’s mRNA flu vaccine.
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase 3 win last week for their cancer vaccine plus Keytruda in melanoma.
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress Resolution Therapeutics completes enrollment in Phase I/II EMERALD clinical trial evaluating RTX001 in end-stage liver disease Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34 Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients SOTIO Doses First Patient in Phase 1/2 CADENCIA-01 Clinical Trial of SOT109, a CDH17-Targeting ADC for Colorectal Cancer BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer Marengo Therapeutics Completes Enrollment in Phase 1/2 STARt-001 Monotherapy Cohorts and Strengthens Leadership to Advance Invikafusp Alfa Toward Late-Stage Development Beeline Medicines Announces Positive Topline Results from Global Phase 2 Study of Afimetoran in Systemic Lupus Erythematosus Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 Leyden Labs Reports Positive Phase 1 Results for RIG-101, Supporting Advancement into Phase 2 to Protect Asthma Patients Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis Encoded Therapeutics Presents Updated Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the 16th European Epilepsy Congress Endeavor BioMedicines Presents New Quantitative Imaging Data from Analysis of Phase 2a Clinical Trial Evaluating Taladegib (ENV-101) in Patients with Idiopathic Pulmonary Fibrosis |
Novartis drags peers down with triple asset stumble
Novartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug The enrollment pause comes after BHV-7000 failed to show efficacy in a midstage depression trial late last year. The news is another regulatory hit for Biohaven after the FDA declined to approve its spinocerebellar ataxia treatment in November 2025.
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’ After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated two other studies of the asset, bringing the total number of high-profile cardiovascular flops to six over nine weeks.
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints While Novartis’ antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity in secondary and exploratory measures.
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons The failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular risk, analysts say—including Eli Lilly and Amgen.
AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study AbbVie’s etentamig has a relatively cleaner safety profile and an administration schedule that could give it an edge over other BCMA-targeting multiple myeloma therapies on the market, according to BMO Capital Markets.
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will need to be replicated in non-Chinese patients.
Ultragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing strategic review The success of apazunersen in a Phase 3 trial for Angelman syndrome was a key driver of Ultragenyx’s value, according to William Blair, and the asset’s failure robs the biotech of any meaningful near-term milestones.
Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it just behind Roche’s own BTK inhibitor fenebrutinib.
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World’s First Phase III Trial of a Generative AI-Driven Innovative Drug Seismic Pharmaceuticals Announces the Enrollment of the First Patient in the Global Phase 3 Trial of Istaroxime in Cardiogenic Shock /UPDATE -- Seismic Pharmaceuticals/ BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence ImPact Biotech Announces Completion of Treatment in Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC and Positive Regulatory Updates New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials Orphalan Initiates Global Phase 3 TRADITiONAL Study of Investigational Once-Daily Trientine Therapy in Wilson Disease Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results Kelun-Biotech’s Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study |
Disc sets up polycythemia vera challenge but Silence maintains lead
The polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the FDA’s approval last month for Mimrylo.
Novartis drags peers down with triple asset stumble Novartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug The enrollment pause comes after BHV-7000 failed to show efficacy in a midstage depression trial late last year. The news is another regulatory hit for Biohaven after the FDA declined to approve its spinocerebellar ataxia treatment in November 2025.
Tyra shares slip as bladder cancer responses fall short of investor expectations Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for non-muscle invasive bladder cancer.
The supply chain fault lines of modern pharma In this episode of Denatured, sponsored by SK pharmteco, Jennifer Smith-Parker speaks to Arvind Singh, vice president and global head of supply chain. In this episode, we explore how CDMOs are reshaping supply‑chain strategy for a new generation of complex modalities.
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx’s big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis’ Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way.
BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’ Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with an upcoming multiple myeloma CAR T therapy from Gilead Sciences, according to BMO Capital Markets.
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s amylin and calcitonin receptor agonist ACCG-2671 showed “impressive” target engagement in a Phase 1 trial of healthy volunteers, according to Leerink Partners.
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress Resolution Therapeutics completes enrollment in Phase I/II EMERALD clinical trial evaluating RTX001 in end-stage liver disease Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer Avenzo Therapeutics to Present Preliminary Phase 1 Study Results of AVZO-1418, a Potentially Differentiated EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium SUMMIT CLINICAL RESEARCH SOLUTIONS EXPANDS PINNACLE SITE NETWORK WITH ACQUISITION OF DALLAS RESEARCH INSTITUTE AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis Community Clinical Research Joins PhaseWell Research to Anchor Inpatient CNS Capabilities and Expand Clinical Trial Access Across Austin and Broader Texas Region Electra Therapeutics Announces Initiation of a Phase 1 Trial of ELA822, a Novel SIRPγ-Specific Antibody Designed to Treat T Cell-Mediated Immune and Inflammatory Diseases Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 Belenos Announces Positive Phase 1b Interim Asthma Results for BEL512, a Long-Acting TSLP/IL-13 Bispecific Antibody Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34 Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World’s First Phase III Trial of a Generative AI-Driven Innovative Drug Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting |
|
|
| |||
|
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer
On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Wed, 09 Sep 2026 00:00:03 -0700
FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
Fri, 04 Sep 2026 00:00:03 -0700
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Wed, 26 Aug 2026 00:00:03 -0700
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma Tue, 25 Aug 2026 00:00:03 -0700
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 13 Aug 2026 00:00:03 -0700
FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Thu, 06 Aug 2026 00:00:03 -0700
FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
Fri, 31 Jul 2026 00:00:03 -0700
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Wed, 22 Jul 2026 00:00:03 -0700
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
Tue, 14 Jul 2026 00:00:03 -0700
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
Tue, 14 Jul 2026 00:00:03 -0700
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
Fri, 10 Jul 2026 00:00:03 -0700
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications.
Thu, 09 Jul 2026 00:00:03 -0700
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.
Tue, 30 Jun 2026 00:00:03 -0700
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC).
Wed, 24 Jun 2026 00:00:03 -0700
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
Wed, 24 Jun 2026 00:00:03 -0700
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.
Fri, 12 Jun 2026 00:00:03 -0700
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Fri, 12 Jun 2026 00:00:03 -0700
FDA approves durvalumab in combination with Bacillus Calmette-Guerin for high-risk non-muscle invasive bladder cancer On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).
Thu, 28 May 2026 00:00:03 -0700
FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wed, 27 May 2026 00:00:03 -0700
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Fri, 22 May 2026 00:00:03 -0700
FDA approves two separate indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.
Fri, 15 May 2026 00:00:03 -0700
FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.
Fri, 15 May 2026 00:00:03 -0700
FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
Wed, 13 May 2026 00:00:03 -0700
FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
Wed, 13 May 2026 00:00:03 -0700
|
Highly efficient CRISPR editing enabled by magnetic nanoparticle delivery.
Front Genome Ed. 2026 Jul 27;8:1865675. doi: 10.3389/fgeed.2026.1865675. eCollection 2026. Go I, Lee SH Amish lethal microcephaly: a new metabolic disorder with severe congenital microcephaly and 2-ketoglutaric aciduria. Am J Med Genet. 2002 Nov 1;112(4):318-26. doi: 10.1002/ajmg.10529. Kelley RI, Robinson D, Puffenberger EG, Strauss KA, Morton DH Global, regional, and national prevalence of second-hand smoke and attributable disease burden in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Public Health. 2026 Sep 7:S2468-2667(26)00168-4. doi: 10.1016/S2468-2667(26)00168-4. GBD 2023 Second-hand smoke Collaborators The moment of truth: stress, lying and the GI tract. Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):291-3. doi: 10.1586/17474124.2.3.291. Pasricha T, Sallam H, Chen J, Pasricha PJ Multidisciplinary blood conservation practices for transfusion-free congenital heart surgery. J Thorac Cardiovasc Surg. 2026 Jul;172(1):209-215.e2. doi: 10.1016/j.jtcvs.2026.01.011. Epub 2026 Jan 22. Carrillo SA, Chenault K, Naguib AN, Voss J, Kelly M, Shutes B, Fitch JA, Blais B, Yerebakan C, Galantowicz M Tozorakimab to Prevent COPD Exacerbations. N Engl J Med. 2026 Sep 8. doi: 10.1056/NEJMoa2606998. Sciurba FC, Watz H, Bourdin A, Janssens W, Martinez FJ, Zheng J, van den Berge M, Bonini M, Han MK, Singh D, Criner GJ, Brightling CE, Papi A, Bhatt SP, Jenkins M, Mikosz M, Chołbiński P, Ziemiecka M, Löfdahl M, Arya D, Yadavalli M, Brodek BH, Fagerås M, Bardsley S, Martin N, Patel R, Psallidas I; OBERON and TITANIA Trial Investigators Searching for explanations: How the Internet inflates estimates of internal knowledge. J Exp Psychol Gen. 2015 Jun;144(3):674-87. doi: 10.1037/xge0000070. Epub 2015 Mar 30. Fisher M, Goddu MK, Keil FC Enhancing HIV-1-specific CAR-T cell functional activity by treatment with a novel cytokine-based scaffold with IL-15 superagonist and TGF-β-neutralizing activity. J Virol. 2026 Aug 14:e0005126. doi: 10.1128/jvi.00051-26. Lamcaj S, Cole E, Hiner C, Santos Bravo M, Zheng JH, Shrestha N, Sowd G, Xiong Y, Zhu Z, Dropulic B, Wong HC, Goldstein H Intratumoral T cell activation kills tumors regardless of T cell specificity. Nat Immunol. 2026 Sep 8. doi: 10.1038/s41590-026-02642-z. Ghirardelli Smith OC, Dao TT, Gavil NV, O'Flanagan SD, Rubin AJ, Nguyen S, Watowich MB, Liu N, Weyu E, Quarnstrom CF, Soerens AG, Joag V, Rosato PC, Krummel MF, Geller MA, Miller JS, Giubellino A, Vezys V, Shalek AK, Masopust D Trends in oesophagus and Stomach cancer incidence in Bangalore, India. Gulf J Oncolog. 2013 Jan;1(13):42-50. Gopala Krishnappa BR, Vijay CR, Ramesh C, Bapsy PP, Kumar MU, Vijayakumar M, Supe SS Treatment Decisions in Multiple Myeloma. N Engl J Med. 2026 Sep 10;395(10):992-1008. doi: 10.1056/NEJMra2605253. Mouhieddine TH, Anderson KC Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials. N Engl J Med. 2026 Sep 9. doi: 10.1056/NEJMoa2601598. Dauvilliers Y, Mignot E, Antczak J, Arnulf I, Barateau L, Buntinx E, Corser B, Iranzo A, Khatami R, Lammers GJ, Lederer K, Nilsen KB, Pizza F, Schmidt MH, Sivam S, Sum-Ping O, Taniguchi M, Zhan S, Abraham A, Cai A, Du Y, Etherton MR, Faessel H, Hsiao S, Kadali H, Koundourakis E, Naylor M, Neuwirth R, Olsson T, Rogers R, Sheikh S, Tanaka S, von Rosenstiel P, von Hehn C, Hang Y, Yao B, Del Rio Villegas R, Plazzi G Paying attention to proprioception: age affects ankle proprioception and the attentional demand of proprioceptive processing in sedentary adults. Geroscience. 2025 Aug;47(4):5803-5823. doi: 10.1007/s11357-025-01609-6. Epub 2025 Mar 26. Vermette MJ, Paré E, Prince F, Messier J Pain alleviation and functional improvement: ultra-early patient-reported outcome measures after full endoscopic spine surgery. J Neurosurg Spine. 2024 Jan 5;40(4):465-474. doi: 10.3171/2023.11.SPINE231048. Print 2024 Apr 1. Leyendecker J, Prasse T, Park C, Payne C, Rückels P, Bieler E, Eysel P, Bredow J, Telfeian A, Derman P, Kashlan O, Konakondla S, Ogunlade J, Hofstetter CP Biofilm formation by ESBL-producing strains of Escherichia coli and Klebsiella pneumoniae. Int J Med Microbiol. 2019 Jan;309(1):13-18. doi: 10.1016/j.ijmm.2018.10.008. Epub 2018 Oct 24. Surgers L, Boyd A, Girard PM, Arlet G, Decré D An operational perturbation proteomics-based virtual cell model. Nature. 2026 Sep 9. doi: 10.1038/s41586-026-11001-9. Sun R, Qian L, Li Y, Liu T, Cheng H, Zhang X, Zhou X, Zhan Y, Zhang G, Luo Z, Ma K, Wu C, Ji D, Xue Z, Meng H, Xiang Y, Lei D, Zhou Q, Hu W, Deng Y, Tan L, Xiao Q, Liu Z, Zeng L, Qian L, Zheng X, Hu Q, Luo N, E W, Zhou P, Wen H, Zhu Y, Guo T Early stage nonsmall cell lung cancer: Toward a risk-adaptive paradigm in the era of biologic precision. CA Cancer J Clin. 2026 Sep-Oct;76(5):e70100. doi: 10.3322/caac.70100. Zhang C, Gu X, Wang P, Li D, Zhang G, Wang T, Wu P, Rao W, Muhammad S, Tan B, Che Y, Zhu M, Qiao Q, Lai F, Zhao B, Fei K, Wu Y, Zhang Z, Dai M, Chen W, Zhang Y, Bi N, Wang J, He J Complete Regression of Hepatoblastoma after Interleukin-15- and Interleukin-21-Coexpressing CAR T-Cell Therapy. N Engl J Med. 2026 Sep 10;395(10):1029-1032. doi: 10.1056/NEJMc2605958. Steffin D, Courtney AN, Choe M, Ghatwai N, Esparza Cerda MA, Sweidan R, Dhanashree R, Zhang H, Lapteva N, Mei Z, Grilley BJ, Metelitsa LS, Heslop HE, Brenner MK, Heczey A Fetal exposure to paracetamol is associated with altered markers of ovarian development and reduced uterine volume in girls: the COPANA study. Hum Reprod Open. 2026 Sep 8;2026(3):hoag073. doi: 10.1093/hropen/hoag073. eCollection 2026. Fischer MB, Mola G, Sundberg K, Scheel L, Wraae KB, Rom AL, Frederiksen H, Anderson RA, Assens M, Andersson AM, Priskorn L, Petersen JH, Hegaard HK, Main KM, Kristensen DM, Juul A, Hagen CP A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia. NEJM Evid. 2026 Sep 9:EVIDoa2600257. doi: 10.1056/EVIDoa2600257. Dauber A, Savarirayan R, Campeau PM, Carroll RS, Cheung M, Cormier-Daire V, de Bergua JM, Edouard T, Gonfiantini MV, Hoover-Fong J, Kannu P, Kinoshita Y, Kubota T, Mendoza-Londono R, Namba N, Ohata Y, Onesimo R, Palm K, Prada CE, Reynaud R, Rossi M, Semler O, Takasawa K, Bassi R, Ghani S, Huntsman Labed A, Osmond D, Sabir I, White J, Maghnie M |
||